| | | | |  |
Larry Ellberger
| | Larry Ellberger has served as a member of our board of directors since August 2006 and Chairman since May 2008. Mr. Ellberger was most recently with PDI, Inc., a provider of sales and marketing services to the biopharmaceutical industry, where he served as interim Chief Executive Officer, and was a member of the Board of Directors and Chairman of the Audit Committee. Prior to PDI, Mr. Ellberger was Senior Vice President, Corporate Development at PowderJect, PLC. During his tenure, PowderJect completed numerous acquisitions and was sold to Chiron Corporation in 2003. He was also a member of PowderJect's Board of Directors. Prior to PowderJect, Mr. Ellberger held several positions at W. R. Grace including Chief Financial Officer, interim CEO, and SVP, Corporate Development. Also, Mr. Ellberger held numerous executive positions, during his 20 years with American Cyanamid Company, a multinational life sciences company until its acquisition by Wyeth in 1995. He received a B.A. in economics from Columbia College and a B.S. in chemical engineering from Columbia School of Engineering. Mr. Ellberger is a Founding Partner of HVA, Inc., an advisory firm for the life sciences industry, and a Director of Avant Immunotherapeutics, Inc. and The Jewish Children's Museum. |
Robert Taub, MBA
| | Robert Taub has served as our president, chief executive officer and a member of our board of directors since the founding of OMRIX in 1995. Prior to establishing OMRIX, Mr. Taub was the cofounder of Octapharma A.G., a Swiss plasma fractionation and pharmaceutical company, which successfully introduced innovative plasma derivative products to the market. During his time at Octapharma, from 1983 to 1995, the company underwent a successful transformation from a start-up operation to an integrated manufacturing enterprise. He also founded a research and development group in Israel and initiated and directed the management of a biological fibrin sealant development project. Prior to Octapharma, Mr. Taub held various general management and sales and marketing positions with Armour Pharmaceutical, Revlon Health Care Group, Baxter Travenol Laboratories, Inc., now Baxter International Inc., and Monsanto Company. He has a B.A. in languages from the University of Antwerp and an M.B.A. from INSEAD (the European Institute of Business Administration) in Fontainebleau, France. |
Bernard Horowitz, Ph.D.
| | Bernard Horowitz, Ph.D. has served as a member of our board of directors since February 2006. Since January 2000, he has been a principal of Horowitz Consultants, LLC, a company providing assistance in strategic planning, process development, viral safety, clinical trial design and new product regulatory compliance. From 1995 to 1999, Dr. Horowitz served as chief scientific officer and executive vice president of V.I. Technologies, Inc., now Panacos Pharmaceuticals, Inc., a now publicly held company he helped found as a spin-out from the New York Blood Center. Dr. Horowitz has served as a scientific consultant to the National Institutes of Health, the Food and Drug Administration, the National Hemophilia Foundation, the International Association of Biological Standardization, and the World Health Organization. Dr. Horowitz received his B.S. in biology from the University of Chicago and his Ph.D. in biochemistry from Cornell University Medical College. He is a director of Protein Therapeutics, Inc. |
Pamela McNamara
| | Pamela W. McNamara has served as a member of our board of directors since May 2008. She has been Chief Executive Officer of CRF, Inc., a clinical trial data management and mobile technology company since October 2003. From February 2002 until October 2003, Ms. McNamara was a private consultant. Ms. McNamara was appointed Chief Executive Officer of Arthur D. Little, Inc., a global management and technology firm, from 2001 to February 2002, to develop plans to restructure, reorganize or divest the firm�s viable business units. In February 2002, Arthur D. Little filed a voluntary petition for reorganization under Chapter 11 of the United States Bankruptcy Code to provide a framework under which these plans could be executed. Ms. McNamara served as Managing Director of Arthur D. Little from 1997 to 2001, and had been a partner since 1992, focusing on the pharmaceutical and biotechnology industries. Ms. McNamara is a director of GTC Biotherapeutics, Inc. and is a former director of Omrix. |
Kevin Rakin
| | Kevin Rakin has served as a member of our board of directors since January 2007. Since January 2006, Mr Rakin has been an Executive-In-Residence at Canaan Partners and Interim CEO of Advanced BioHealing, Inc., a Canaan portfolio company. Mr. Rakin co-founded Genaissance Pharmaceuticals, Inc. and served as its President and Chief Executive Officer from August 2002 until its merger with Clinical Data, Inc., in October 2005. He also served as Genaissance's President and CFO from October 2000 to August 2002 and prior to that as its Executive Vice President & CFO. From 1990 to December 1997, Mr. Rakin served as a Principal at the Stevenson Group, a consulting firm, where he provided financial and strategic planning services to high-growth technology companies and venture capital firms. From 1982 to 1990, Mr. Rakin was a manager with the entrepreneurial services group of Ernst & Young LLP. Mr. Rakin holds a B.S. in business and a M.S. in finance from the University of Cape Town and a M.B.A. from Columbia University. |
Philippe Romagnoli
| | Philippe Romagnoli has served as a member of our board of directors since January 2007. From April 2004 to January 2007 he was our vice president and secretary. From September 2002 to April 2004, he was our interim chief financial officer and a member of our board of directors. Prior to joining OMRIX, from 1998 to 2002, he was the chairman of the board of Artesia Bank and from 1992 until 1998, the chief executive officer of Banque Paribas Belgium. Mr. Romagnoli holds an engineering degree with a specialty in physics from the University of Li`eìe Belgium.
|
Steven St. Peter, M.D.
| | Steven St. Peter, M.D. has served as a member of our board of directors since February 2004. He joined MPM Capital L.P. as a principal in 2004 and became a general partner in 2005. Prior to joining MPM, from 2001 to 2003, he was a principal at Apax Partners and from 1999 to 2001, he was a senior associate at The Carlyle Group. His investment scope has included both venture and buyout transactions across the medical technology and biopharmaceutical industries. Dr. St. Peter is board certified in internal medicine and was previously an assistant clinical professor of Medicine at Columbia University. He completed his doctor of medicine at Washington University. Prior to his medical training, he was an investment banker at Merrill Lynch. He also holds an M.B.A. from the Wharton School of the University of Pennsylvania and a B.A. in Chemistry from the University of Kansas. He is a director of Helicos BioSciences Corporation, PharmAthene, Inc. and Xanodyne Pharmaceuticals Inc. |
| |
| |
about us
